Declaration of Competing Interest All authors received nonfinancial support (assistance with manuscript preparation) from ArticulateScience LLC, funded by AstraZeneca. Additional disclosures are as follows: SMS reports grants/contracts from Breast Cancer Research Foundation, Genentech/Roche, and Kailos Genetics, consulting fees from AstraZeneca, Daiichi Sankyo, Molecular Templates, Silverback Therapeutics, Eli Lilly, Merck, Natera, Exact Sciences, Athenex, Biotheranostics, and Genentech/Roche, honoraria from Genentech/Roche, Daiichi Sankyo, and Beijing Medical Foundation, 3rd party writing in kind Genentech/Roche travel support from Genentech/ Roche, Caris, and Daiichi Sankyo, serving on Data and Safety Monitoring Committee for AstraZeneca, and leadership or a fiduciary role for ASCO Conquer Cancer Foundation and The National Surgical Adjuvant Breast and Bowel Project Foundation, outside of the submitted work; MN reports grants/contracts to the institution from Canon Medical Systems, AstraZeneca, and Daiichi Sankyo, and consulting fees from AstraZeneca and Daiichi Sankyo, outside of the submitted work; LHL reports grants/ contracts from FibroGen, Novartis, Celgene, Biogen, Pliant, Galecto, Boehringer Ingelheim, Respivant, Bristol Myers Squibb, Genentech, and Galapagos, consulting fees from AstraZeneca, Boehringer Ingelheim, Genentech, Galapagos, Veracyte, and DevPro Biopharma, honoraria from Genentech, Boehringer Ingelheim, and Veracyte, serving on advisory/data safety monitoring boards or steering committees for Senhwa, Bellerophon, and United Therapeutics, and leadership or a fiduciary role for Pulmonary Fibrosis Foundation Registry Steering Committee, outside of the submitted work; BTL reports grants/contracts from the National Institutes of Health, AstraZeneca, and Daiichi Sankyo, during the submitted work, and grants/contracts from Amgen, Eli Lilly, Genentech/Roche, Hengrui USA, and Bolt Biotherapeutics, royalties or licenses from Karger Publishers and Shanghai Jiao Tong University Press, travel support from MORE Health and Jiangsu Hengrui Medicine, and two institutional patents at Memorial Sloan Kettering Cancer Center (US62/685,057, US62/514,661), outside of the submitted work; AGN reports consulting fees from Galapagos, Boehringer Ingelheim, Roche, and Medical Quantitative Image Analysis, and honoraria from UpToDate and Boehringer Ingelheim, outside of the submitted work; BJB reports grants/contracts from the National Institutes of Health/National Cancer Institute and Hurvis Foundation, royalties from Imbio, consulting fees from AstraZeneca, and two patents (patent number: 11026641; publication number: 20180061049), outside of the submitted work; JN reports grants/contracts from Merck, AstraZeneca, and Bristol Myers Squibb, consulting fees from Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Daiichi Sankyo, Takeda, and Roche/Genentech, honoraria from Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Takeda, and Roche/ Genentech, travel support from Merck, and serving on advisory boards for Daiichi Sankyo, outside of the submitted work; KS reports grants/ contracts from Astellas, Eli Lilly, Ono, Sumitomo Dainippon, Daiichi Sankyo, Taiho, Chugai, MSD, Medi Science, and Eisai, consulting fees from Astellas, Eli Lilly, Bristol Myers Squibb, Takeda, Pfizer, Ono, MSD, Taiho, Novartis, AbbVie, GlaxoSmithKline, Daiichi Sankyo, Amgen, and Boehringer Ingelheim, and honoraria from Novartis, AbbVie, and Yakult, outside of the submitted work; JT reports travel support and honoraria from Daiichi Sankyo, and serving on advisory boards for Daiichi Sankyo, outside of the submitted work; TK reports grants/contracts from Regeneron, AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Chugai, Eli Lilly, Merck Biopharma, MSD, Novartis, Ono, Pfizer, and Taiho, payment or honoraria from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Merck Biopharma, MSD, Novartis, Ono, Pfizer, and Roche, serving on advisory/ data safety monitoring boards with honoraria for AbbVie, Amgen, AstraZeneca, Chugai, Daiichi-Sankyo, Eli Lilly, Merck Biopharma, MSD, Nippon Kayaku, Novartis, Ono, Pfizer, Taiho, and Takeda, and spousal employment at Eli Lilly, outside of the submitted work; FA reports grants/contracts from AstraZeneca, Daiichi Sankyo, Novartis, Sanofi, Roche Genentech, Lilly, and Pfizer, travel support from Pfizer, and serving on advisory boards for AstraZeneca, Daiichi Sankyo, Novartis, Sanofi, Roche/Genentech, Eli Lilly, and Pfizer, outside of the submitted work; and CAP reports personal fees from Daiichi Sankyo, AstraZeneca, Voluntis, Bristol Meyers Squibb, Senhwa Biosciences, and Eisai, outside of the submitted work.